Gavriel Mullokandov

Founder, Vice President, Corporate Development

Gavriel Mullokandov, MD, PhD, led the company’s formation and has been instrumental in establishing Marrow’s funding strategy, raising $173 million from seed through Series B. He brings deep scientific expertise in immunology and microRNA biology from his PhD research at the Immunology Institute at Mount Sinai, where he developed novel high-throughput genetic screening tools and collaborated across multiple disciplines to advance translational research.

Dr. Mullokandov completed his clinical training in clinical pathology at Weill Cornell Medical College as part of the Physician Scientist Training Program. He holds an MD/PhD from the Icahn School of Medicine at Mount Sinai and a BA in biochemistry from Columbia University, where he graduated magna cum laude.